From Monday 1 July 2019, the National Disability Insurance Scheme (NDIS) will be introducing its Quality and Safeguarding Framework (QSF) into Tasmania via the operation of an independent Quality and Safeguards Commission.
The Commission will bring a nationally consistent approach to the reduction and elimination of the use of restrictive practises, including a set of definitions for seclusion, physical restraint, mechanical restraint, environmental restraint and chemical restraint.
'Chemical restraint' will be defined as:
‘the use of medication or chemical substance for the primary purpose of influencing a person’s behaviour or movement. It does not include the use of medication prescribed by a medical practitioner for the treatment of, or to enable treatment, of a diagnosed mental disorder, a physical illness or physical condition.’
The Commission will require registered disability service providers to report to them any use of a regulated restrictive practice. The service provider will also need to arrange for a behaviour support plan to be developed for the person with disability being subject to a restrictive practice. Registered service providers may therefore need to seek advice from the client’s GP to understand whether a medication is prescribed to treat a physical condition, a mental illness or for behaviour management.
It is important to note that the use of medication to control a person’s behaviour maybe the best current option, particularly in the short term or in instances where significant harm to the patient and others is likely. Administration of such medication in these situations ‘buys time’ for the development of a positive behaviour support plan and the implementation of strategies that may then allow medical practitioners to safely reduce and cease the patient’s medication use if it has been prescribed for behaviour modification purposes.
In order to help service providers and medical practitioners with this new requirement, the Office of the Senior Practitioner (Tasmania) has developed a ‘Purpose of Medication’ form and fact sheets on chemical restraint available on the Department of Health and Human Services website.
If medical practitioners have any questions about these new arrangements,
email the Commission or phone 1800 035 544.